Hypothesis

During cellular senescence, the gain of H3K27me3 at gene‑rich regions is not a passive consequence of global chromatin loss but is actively driven by a phase‑separated condensate formed between the intrinsically disordered region (IDR) of EZH2 and residual LMNB1 fragments at the nuclear periphery. This condensate concentrates EZH2 activity, enabling localized H3K27me3 deposition despite overall LMNB1 depletion. Disrupting the EZH2‑IDR/LMNB1 interaction should prevent the paradoxical H3K27me3 gain, block senescence‑associated heterochromatic foci (SAHF) formation, and attenuate the senescence‑associated secretory phenotype (SASP) without affecting global LMNB1 levels.

Mechanistic Rationale

• Phase separation as a spatial organizer: Recent work shows that many chromatin modifiers, including EZH2, contain low‑complexity IDRs that promote biomolecular condensates (3). In senescence, LMNB1 depletion from LADs exposes lamin‑associated chromatin, creating a sticky scaffold that can nucleate EZH2 IDR‑dependent droplets.
• Coupling to H3K27me3 activity: Within these droplets, EZH2’s catalytic SET domain is highly concentrated, increasing its effective concentration toward nucleosomes that become transiently accessible as H3K9me3 and H3K27me3 globally retreat from LADs (1). This explains the observed local H3K27me3 gain at gene‑rich sites while the bulk mark declines.
• Link to SAHF and SASP: SAHFs are thought to lock away proliferation‑promoting genes; however, SASP drivers escape silencing. If EZH2 IDR‑mediated droplets mislocalize repressive H3K27me3 to SASP promoters, they could fine‑tune rather than fully repress these loci, producing the mixed activation/repression signature observed in senescent cells (4).

Testable Predictions

1. EZH2 IDR mutation reduces focal H3K27me3: Introducing point mutations that disrupt the EZH2 IDR (e.g., deletion of the S‑rich stretch) in human fibroblasts will diminish H3K27me3 ChIP‑seq peaks at gene‑rich regions after irradiation‑induced senescence, while global H3K27me3 levels remain unchanged.
2. SAHF formation is impaired: Immunofluorescence for H3K9me3 and LMNB1 will show fewer and smaller SAHFs in EZH2 IDR‑mutant senescent cells compared with wild‑type controls.
3. SASP attenuation without affecting proliferation arrest: ELISA for IL‑6, IL‑8, and MMP‑3 will reveal a ≥50% reduction in secreted SASP factors, whereas p16^INK4a^ and p21^CIP1^ expression and EdU incorporation remain comparable to wild‑type senescent cells.
4. Rescue by synthetic IDR fusion: Expressing a heterologous IDR (e.g., from FUS) fused to EZH2’s SET domain in the IDR‑mutant background restores focal H3K27me3, SAHF number, and SASP levels to near‑wild‑type phenotypes.
5. Pharmacological disruption: A small molecule that interferes with EZH2 IDR‑LMNB1 interaction (identified via in‑vitro droplet assay) will phenocopy the genetic mutations, providing a therapeutic avenue to modulate senescence without globally inhibiting EZH2 methyltransferase activity.

Falsifiability

If EZH2 IDR mutants show no change in focal H3K27me3, SAHF formation, or SASP secretion relative to wild‑type senescent cells, the hypothesis is refuted. Conversely, if global EZH2 inhibition (e.g., GSK126) phenocopies the IDR mutant effects, it would suggest that catalytic activity, not phase separation, drives the observations, also falsifying the specific mechanistic claim.

Broader Implications

Validating this model would reposition epigenetic dysregulation in senescence from a passive collapse to an active, biophysically driven reorganization. It would highlight IDR‑mediated phase separation as a druggable node to decouple harmful SASP from stable cell‑cycle arrest, offering a strategy to mitigate age‑related tissue dysfunction while preserving tumor suppressor functions.